

Preliminary Program as of March 9, 2007

Thursday, March 22, 2007

9:30 – 11:00 OPEN Workshop – Topical Anti-psoriatics in 2007

An interactive session reviewing and discussing:

- the characteristics / classification of psoriatic patients
- treatment classes/formulations and matching them with different patients and caregivers
- the characteristics of optimal topical therapy
- the data on / use of different topical therapies (tars, anthralin, Dovobet®)
- the factors affecting patient compliance
- the effect of compliance on disease management success
- the characteristics of various topicals in relation to these characteristics

Presenters:

Moderator: Dr. Richard Thomas

Speakers: Dr. Lyn Guenther, Dr. Leon Kircik, Dr. Richard Thomas

Time	Topic	Leader
9:00	Welcome, Agenda Review, Objectives	Dr. Richard Thomas
9:05	Best strategies to manage psoriasis with limited health care resources	Dr. Richard Thomas
9:25	Topical medications review	Dr. Lyn Guenther
9:50	Compliance/Adherence with topicals	Dr. Leon Kircik
10:15	Other / special/ off-label uses	Dr. Richard Thomas
10:25	Summary	Dr. Richard Thomas

2:00 – 3:30 OPEN Workshop – Imiquimod Synergies with Surgery

Faulty: Dr. Mariusz Sapijaszko, Dr. Neil Bhatia, Dr. Lyn Guenther

4:00 – 5:20 Plenary Session 1

4:00 – 4:20	The Safety and Efficacy of Efalizumab for Treatment of Hand and Foot Psoriasis	Dr. Chuck Lynde
4:20 – 4:40	Patient Advocacy	tba
4:40 – 5:00	The Role of the Dermatologist in Identifying and Treating the Early Stages of PsA	Dr. Sergio Chimenti
5:00 – 5:20	Panel and Questions	

Friday, March 23, 2007

9:30 – 11:00 OPEN Workshop – Infliximab in the Real World

Faculty: Dr. Robert Bissonnette, Dr. Richard Langley, Dr. Sergio Chimentes

Chair:

Robert Bissonnette, MD
Assistant Professor
University of Montreal, Quebec

Long Term Experience with Infliximab in the Real World

Sergio Chimenti, MD
Professor and Chairman Department of Dermatology,
University of Rome, Italy

How to initiate infliximab treatment in a general dermatology practice

Robert Bissonnette, MD
Assistant Professor
University of Montreal, Quebec

Managing Moderate to Severe Psoriasis: A case based Approach

Richard Langley, MD
Assistant Professor Dalhousie
University Halifax, NS

11:30 – 1:30 OPEN Workshop – Therapeutic Options in the Pediatric Psoriasis Population

Objectives:

- Provide participants with an overview of disease prevalence and pathogenesis of pediatric psoriasis
- Evaluate current and future therapeutic options for the treatment of pediatric psoriasis
- Review available safety and efficacy data on the use of etanercept for the treatment of inflammatory diseases in pediatric population
- Review practical case studies of therapeutic options and treatment in the pediatric psoriasis population

PART 1: 11:30-12:00 -Dr. Danielle Marcoux (chair)

- *Introduction and Objectives*
- *Overview of pediatric psoriasis (e.g. prevalence, burden of the disease, pathogenesis)*

PART 2: 12:00-12:30 -Dr. Richard Langley

- Overview of therapies currently available (now and future) for pediatric psoriasis)

PART 3: 12:30-1:00 -Dr. Ian Landells

- Highlight the latest clinical trial data for Enbrel in JRA (safety)
- Outline the study design for the ped psoriasis trial
- Case studies of pediatric psoriasis

PART 4: 1:00-1:05 -Dr. Danielle Marcoux

- Chair summary

PART 5: 1:05-1:30 -Panel

- *Audience Q&A*

4:30 – 5:45 Plenary Session 2

4:30 – 5:00	Gene Environment Interactions in Atopic Eczema: Implications for Treatment	Dr. Michael Cork
5:00 – 5:15	TBA	
5:15 – 5:30	Spectra and the Sun	Dr. Joel Claveau
5:30 – 5:45	Panel and Questions	

5:45 – 8:00 Cocktail Reception

Saturday, March 24, 2007

7:30 – 8:30 *Buffet Breakfast*

8:30 – 9:55 **Plenary Session 3**

8:30 – 9:00	Skin Therapy Update	Dr. Stuart Maddin
9:00 – 9:20	The Scientific Art of Topical Formulations	Dr. Marco Taglietti
9:20 – 9:40	Advances in pemphigus therapy	Dr. Regine Mydlarski
9:40 – 9:55	Panel and Questions	

9:55 – 10:10 *Coffee Breaks and Poster Exhibits*

10:10 – 11:25 **Plenary Session 4**

10:10 – 10:30	Nevus: Concepts and Controversies in 2007	Dr. Jason Rivers
10:30 – 10:50	tba	Dr. Neil Bhatia
10:50 – 11:10	tba	tba
11:10 – 11:25	Panel and Questions	

11:30 – 1:30 *Lunch*

2:00 – 3:20 **Plenary Session 5**

2:00 – 2:20	Who...When and Why to patch test'	Dr. Melanie Pratt
2:20 – 2:40	Androgen Alopecia	Dr. Jerry Shapiro
2:40 – 3:00	The Role of Metabolic Syndrome in Dermatology	tba
3:00 – 3:20	Panel and Questions	

3:20 – 3:40 *Coffee Breaks and Poster Exhibits*

3:40 – 4:20 **Plenary Session 6**

3:40 – 4:00	PDT and its role in 2007	Dr. Robert Bissonnette
4:00 – 4:20	New Approaches for the Treatment of Onychomycosis and Seborrheic Dermatitis	Dr. Aditya Gupta
4:20 – 4:40	Review of Fillers Available in Canada	tba
4:40 – 5:00	Panel and Questions	

5:00 – 5:15 **Closing Comments** Dr. Stuart Maddin

Derm Update Clinical Trial Workshop
Sunday March 25, 2007
07:30 – 10:30

Chaired by: Lynne Bulger and Dr. Paul Kidson

Welcome and overview of the agenda

PART I

Clinical Trial Agreements – Contracts

What you need to know before signing.

Site Selection

From the perspective of a major CRO - Quintiles

Metrics – Tracking your performance

How to promote your site effectively

PART II

Developing and maintaining core competencies in derm clinical trials

How can we create a network of excellence?

Pitfalls in assessments:

Psoriasis: PASI scoring

Atopic Dermatitis: IGA

Acne: Lesion Counting

Onychomycosis KOH and mycology cultures

Summary

What have we learned about:

- *Improving our sites performance?*
- *Improving our core competencies?*
- *Promoting our sites and our unique clinical trial abilities?*

REGISTRATION FORM:

Name: _____

Affiliation: _____

Telephone: _____ Fax: _____ Email: _____

Fee: \$200.00 + gst = \$212.00

Method of Payment

[] Visa [] MasterCard

Card Number: _____

Expiry Date: _____ Name of Cardholder: _____

PLEASE FAX TO 604-738-8697 BEFORE MARCH 15
MINIMUM 16 PARTICIPANTS REQUIRED